Konstantin H. Dragnev MD

Institution Affiliations:

Associate Professor of Medicine

Department of: MEDICINE

Section: Hematology/Oncology

Specialty: Medical Oncology

Joined Staff: 1999

Cancer Center Membership:

Comprehensive Thoracic Clinical Oncology Group

Cancer Epidemiology and Chemoprevention Research Program

Molecular Therapeutics Research Program

Degree(s): MD

Higher Institute of Medicine, Sofia, Bulgaria 1987

Internship(s):

Residency:

District Hospital, Lukovit, Bulgaria, (Internal Medicine) 1987-89

Baylor College of Medicine, Houston, TX, (Internal Medicine) 1993-96

Fellowship(s):

Bulgarian Medical Academy, Sofia, Bulgaria, (Oncology) 1989-91

National Cancer Institute, National Institutes of Health, Bethesda, MD, (Research) , Frederick Cancer Research & Development Center 1991-93

Memorial Sloan-Kettering Cancer Center, New York, NY, (Hematology/Oncology) 1996-98

Dartmouth-Hitchcock Medical Center, Lebanon, NH, (Hematology/Oncology) 1998-99

Biography:

Dr. Dragnev received his MD in 1987 from the Higher Institute of Medicine in Sofia, Bulgaria. Following a residency in Internal Medicine at Baylor College of Medicine, Dr. Dragnev entered the H/O Fellowship Program at the Memorial Sloan Kettering in 1996; in 1998 he transferred to the Dartmouth Hitchcock Medical Center to complete his third year of fellowship. On July 1, 1999 he joined the staff of the Section of Hematology/Oncology at the DHMC as a lung cancer specialist.

Research Interests:

Dr. Dragnev is the Principal Investigator of several studies evaluating novel approaches for the treatment of lung cancer using molecularly targeted agents.

Selected Publications:

Dragnev, K. H., Pitha-Rowe, I., Ma, Y., Petty, W. J., Sekula, D., Murphy, B., Rendi, M., Suh, N., Desai, N. B., Sporn, M. B., Freemantle, S. J., and Dmitrovsky, E. Specific chemopreventive agents trigger proteasomal degradation of G1 cyclins: implications for combination therapy Clin Cancer Res, 10: 2570-2577, 2004.

Pitha-Rowe I, Petty WJ, Feng Q, Koza-Taylor PH, Dimattia DA, Pinder L, Dragnev KH, Memoli N, Memoli V, Turi T, Beebe J, Kitareewan S, Dmitrovsky E. Microarray analyses uncover UBE1L as a candidate target gene for lung cancer chemoprevention. Cancer Res, 64:8109-15, 2004.

Petty, W. J., Dragnev, K. H., Memoli, V. A., Ma, Y., Desai, N. B., Biddle, A., Davis, T. H., Nugent, W. C., Memoli, N., Hamilton, M., Iwata, K. K., Rigas, J. R., and Dmitrovsky, E. Epidermal growth factor receptor tyrosine kinase inhibition represses cyclin D1 in aerodigestive tract cancers. Clin Cancer Res, 10:7547-7554, 2004.

Dragnev, K. H., Petty, W. J., Shah, S., Biddle, A., Desai, N., Memoli, V., Rigas, J. R., and Dmitrovsky, E. Bexarotene and erlotinib for aerodigestive tract cancer. J Clin Oncol, 23:8757-64, 2005.